Posts tagged neutral
Ladenburg ups Intra-Cellular to buy

Ladenburg Thalmann upgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “buy” from “neutral” with a $36 price target, reflecting a positive update from the FDA about the company’s schizophrenia program. The stock closed at $15.90 on August 29.

Read More
Ladenburg up Novavax to buy

Ladenburg Thalmann upgraded Novavax (NASDAQ:NVAX) to “buy” from “neutral” with a new price target of $1.60 after the company presented encouraging preclinical data from its nanoparticle influenza vaccine, NanoFlu, and outlined a clinical development strategy targeting older adults. The stock closed at 97 cents on Aug. 8.

Read More
Roth ups iRadimed to buy

Roth Capital Partners upgraded iRadimed (NASDAQ:IRMD) to “buy” from “neutral” and raised its price target to $12 from $9 after the company reported second quarter results. The stock closed at $9.80 on July 31.

Read More
HCW downgrades Inotek to neutral

H.C. Wainwright downgraded Inotek Pharmaceuticals (NASDAQ:ITEK) to “neutral” from “buy” and slashed its price target to $2 from $7 after a failed Phase 2 trial. The stock closed at 96 cents on July 11.

Read More
HCW upgrades Galectin to buy

H.C. Wainwright upgraded Galectin Therapeutics (NASDAQ:GALT) to “buy” from “neutral” and raised its price target to $3 from 60 cents, citing a more positive view of the therapeutic potential of the mechanism of galectin-3 inhibition. The stock closed at $1.98 on March 29.

Read More
Roth downgrades ANI Pharma to neutral

Roth Capital Partners downgraded ANI Pharmaceuticals (NASDAQ:ANIP) to “neutral” from “buy,” pending the company’s 2017 financial guidance. Roth maintained its $69 price target for the stock, which was quoted at $59.53, down $3.52, in the afternoon session on Feb. 22.

Read More
HCW upgrades CymaBay to buy

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on Jan. 27.

Read More
Ladenburg upgrades Repros Therapeutics to buy

Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ:RPRX) to “buy” from “neutral,” with a new price target of $5.50. The stock closed at $1.93 on Wednesday.

In a new report, analyst Matthew Kaplan writes that Repros has announced positive Phase 2b data for both its oral and vaginal delivery trials, following two, 18-week cycles of treatment with Proellex for the treatment of uterine fibroids.

Read More
Roth upgrades Applied Genetic to buy

Roth Capital Partners upgraded Applied Genetic Technologies (NASDAQ:AGTC) to “buy” from “neutral” and raised its price target to $15 from $12. The stock jumped $2.15 to $9.20 in afternoon trading on Wednesday.

“With F1Q17 results in hand, we see accelerated movement and mindful planning in the clinical programs for X-linked retinoschisis (XLRS) and achromatopsia (ACHM), as certain groups from these studies have completed enrollment and patients eligible to participate in future phases of these studies have been vetted,” writes analyst Joseph Pantginis.

Read More
HCW downgrades Agenus to neutral

H.C. Wainwright downgraded Agenus (NASDAQ:AGEN) to “neutral” from “buy” and slashed its price target to $5 from $10. The stock closed at $4.33 on Thursday.

Analyst Swayampakula Ramakanth writes that during Agenus’ third quarter earnings, the company announced development of CTLA-4 and PD-1 checkpoint modulators (CPMs) as the focus of the company’s cancer immunotherapy pipeline.

Read More
Roth downgrades iRadimed to neutral

Roth Capital Partners downgraded iRadimed (NASDAQ:IRMD) to “neutral” from “buy” with a new price target of $11.50 after the company pre-announced a third quarter miss and reduced its 2016 outlook. The stock closed at $10.77 on Tuesday.

Analyst Chris Lewis writes that the announcement leaves him “incrementally cautious on the near-term pump growth profile and lengthening sales cycle.”

Read More
BTIG downgrades NeoGenomics to neutral

BTIG Research downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy.” The stock closed at $9.05 on Tuesday.

Analyst Dr. Sean Lavin writes that second quarter results were largely in-line. “The base business continues to trend well and with more clarity around Medicare in 2017, we think downside risk is fairly modest,” he said.

Read More
BTIG starts Insulet, Intersect at neutral

BTIG Research initiated research of Insulet (NASDAQ:PODD) and Intersect ENT (NASDAQ:XENT) with “neutral” ratings. Shares of Insulet closed at $32.21 and shares of Intersect at $13.51 on Tuesday.

Analyst Sean Lavin writes that he sees Insulet’s core business as fairly valued at five times next 12 months revenue as both the major upside events and key risks are hard to forecast in terms of timing. 

Read More